COPERNICUS Tests Prophylaxis With Subcutaneous Amivantamab

Company Johnson & Johnson Innovative Medicine / Janssen Biotech Event Type Clinical Trial Results (Phase IIb Interim Analysis) Modality Subcutaneous Bispecific Antibody + Oral TKI Combination With Prophylaxis Protocol Asset Amivantamab (RYBREVANT FASPRO) plus Lazertinib (LAZCLUZE) Target EGFR and MET (amivantamab); EGFR (lazertinib) Disease Area…